Medicines shortages: regulatory processes to manage supply disruptions

AI Summary

This document outlines the Medicines and Healthcare products Regulatory Agency’s (MHRA) strategic approach to managing medical product supply disruptions within the United Kingdom. As the nation's primary regulator for medicines and medical devices, the MHRA operates under a regulatory framework designed to protect public health by ensuring the continuous availability of essential treatments. The guidance specifies that the agency will prioritize the assessment of new product applications and modifications to existing product licenses when a potential shortage is identified. This expedited review process is intended to facilitate the entry of alternative supplies into the market to mitigate health risks. While the provided text does not reference specific company violations, inspection dates, or enforcement actions, it highlights a recent educational initiative via a webinar held in November 2024. Required actions for stakeholders involve understanding these prioritization protocols and utilizing the MHRA’s formal processes to report and address supply gaps. The agency remains focused on using its regulatory oversight to streamline the approval of critical products during supply crises.